Plus Therapeutics (PSTV) said Thursday that its Rhenium obisbemeda radiotherapy has been granted orphan drug designation by the US Food and Drug Administration for treating leptomeningeal metastases in lung cancer patients.
The company said the designation follows the completion of its phase 1 single-dose trial, which established the recommended Phase 2 dose. Plus Therapeutics is advancing a Phase 2 single-dose expansion trial and a Phase 1 multiple-dose trial.
Shares of Plus Therapeutics surged past 36% in recent Thursday trading.
Price: 0.48, Change: +0.13, Percent Change: +36.57
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.